References
- Okanoue T., Sakamoto S., Itoh Y., Minami M., Yasui K., Sakamoto M., et al. Side effects of high‐dose interferon therapy for chronic hepatitis C. J Hepatol 1996; 25: 283–91
- Ronnblom L. E., Alm G. V., Oberg K. E. Autoimmunity after alpha‐interferon therapy for malignant carcinoid tumors. Ann Intern Med 1991; 115: 178–83
- Ioannou Y., Isenberg D. A. Current evidence for the induction of autoimmune rheumatic manifestations by cytokine therapy. Arthritis Rheum 2000; 43: 1431–42
- PRISMS (prevention of relapses and disability by interferon‐beta‐1a subcutaneously in multiple sclerosis) Study Group and University of British Columbia MS/MRI Analysis Group. PRISMS‐4: long term efficacy of interferon‐beta‐1a in relapsing MS. Neurology 2001; 56: 1628–36
- Monzani F., Meucci G., Caraccio N., Saviozzi M., Casolaro A., Moscato G., et al. Discordant effect of IFN‐beta1a therapy on anti‐IFN antibodies and thyroid disease development in patients with multiple sclerosis. J Interferon Cytokine Res 2002; 22: 773–81
- Durelli L., Bongioanni M. R., Ferrero B., Oggero A., Marzano A., Rizzetto M. Interferon treatment for multiple sclerosis: autoimmune complications may be lethal. Neurology 1998; 50: 570–1
- Nousari H. C., Kimyai‐Asadi A., Tausk F. A. Subacute cutaneous lupus erythematosus associated with interferon beta‐1A. Lancet 1998; 352: 1825–6
- Blake G., Murphy S. Onset of myasthenia gravis in a patient with multiple sclerosis during interferon‐1B treatment. Neurology 1997; 49: 1747–8
- Noronha A., Toscas A., Jensen M. A. Interferon beta decreases T cell activation and interferon gamma production in multiple sclerosis. J Neuroimmunol 1993; 46: 145–53
- Tak P. P. IFN‐beta in rheumatoid arthritis. Frontiers Biosci 2004; 9: 3242–7
- Okada K., Kuroda E., Yoshida Y., Yamashita U., Suzumura A., Tsuji S. Effects of interferon‐β on the cytokine production of astrocytes. J Neuroimmunol 2005; 159: 48–54
- Pilling D., Akbar A. N., Girdlestone J., Orteu C. H., Borthwick N. J., Amft N., et al. Interferon‐beta mediates stromal cell rescue of T cells from apoptosis. Eur J Immunol 1999; 29: 1041–50
- Jabaily J. A., Thompson J. S. Effects of interferon beta‐1B in rheumatoid arthritis: a case report. Arthritis Rheum 1997; 40: 1370
- Van Holten J., Reedquist K., Sattonet‐Roche P., Smeets T. J., Plater‐Zyberk C., Vervoordeldonk M. J., Tak P. P. Treatment with recombinant interferon‐beta reduces inflammation and slows cartilage destruction in the collagen‐induced arthritis model of rheumatoid arthritis. Arthritis Res Ther 2004; 6: R239–49
- Tak P. P., 't Hart B. A., Krann M. C., Jonker M., Smeets T. J. M., Breedveld F. C. The effects of interferon beta treatment on arthritis. Rheumatology 1999; 38: 362–9
- Genovese M. C., Chakravarty E. F., Krishnan E., Moreland L. W. A randomized, controlled trial of interferon‐beta‐1a (Avonex®) in patients with rheumatoid arthritis: a pilot study. Arthritis Res Ther 2004; 6: R73–7
- Van Holten J., Pavelka K., Vencovsky J., Stahl H., Rozman B., Genovese M., et al. A multicentre, randomized, double blind, placebo controlled phase II study of subcutaneous interferon beta‐1a in the treatment of patients with active rheumatoid arthritis. Ann Rheum Dis 2005; 64: 64–9
- Alsalameh S., Manger B., Kern P., Kalden J. New onset of rheumatoid arthritis during interferon beta‐1B treatment in a patient with multiple sclerosis: comment on the case report by Jabaily and Thompson. Arthritis Rheum 1998; 41: 754
- Russo R., Tenembaum S., Moreno M. J., Battagliotti C. Interferon beta‐1A induced juvenile chronic arthritis in a genetically predisposed young patient with multiple sclerosis: comment on the case report by Levesque et al. Arthritis Rheum 2000; 43: 1190
- Altintas A., Alici Y., Melikoglu M., Siva A. Arthritis during interferon beta‐1B treatment in multiple sclerosis. Multiple Sclerosis 2002; 8: 534–6
- Karow A. C., Braun J., Marx P., Stangel M. Remission of a CNS inflammatory disease accompanied by newly developed ANA and arthropathy during treatment with INF‐beta. J Neurol 2002; 249: 1121–2